Market research
OBSV ObsEva SA
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 0.67
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- CH0346177709
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 0.67
About
About ObsEva SA
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OBSV discussion.
5 years, 4 months ago
ObsEva SA is currently in a long term downtrend where the price is trading 2.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
ObsEva SA's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 10.6% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 4.8% to $-22M since the same quarter in the previous year.
Based on the above factors, ObsEva SA gets an overall score of 3/5.